help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on March 27, 2009, doi:10.1165/rcmb.2008-0275OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2008-0275OCv1
42/1/80    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Supinski, G. S.
Right arrow Articles by Callahan, L. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Supinski, G. S.
Right arrow Articles by Callahan, L. A.
American Journal of Respiratory Cell and Molecular Biology. Vol. 42, pp. 80-87, 2010
© 2010 American Thoracic Society
DOI: 10.1165/rcmb.2008-0275OC

Calpain Activation Contributes to Endotoxin-Induced Diaphragmatic Dysfunction

Gerald S. Supinski1 and Leigh Ann Callahan1

1 Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, Kentucky

Correspondence and requests for reprints should be addressed to Gerald S. Supinski, M.D., Department of Medicine, 740 South Limestone, K-528, University of Kentucky, Lexington, KY 40536-0284. E-mail: gsupi2{at}email.uky.edu

Calpain activation occurs in skeletal muscle in response to infection, but it is unknown if calpain inhibition improves muscle functional capacity. We hypothesized that infection induces diaphragm calpain activation, that calpain activation results in cleavage of important diaphragm cytoskeletal proteins, and that inhibition of calpain attenuates infection-induced diaphragm dysfunction. Mice (n = 4–6/group) were given: (1) saline (intraperitoneal); (2) endotoxin (12 mg/kg intraperitoneal); (3) calpain inhibitor peptide III (12 mg/kg intraperitoneal); and (4) endotoxin (12 mg/kg) plus calpain inhibitor peptide III (12 mg/kg). At 24 hours, diaphragms were removed and the following determined: (1) calpain activity by fluorogenic assay; (2) calpain I and II protein levels; (3) talin protein levels; and (4) the force–frequency relationship. Endotoxin significantly increased diaphragm calpain activity (P < 0.001), active calpain I protein (P < 0.001), active calpain II protein (P < 0.01), levels of a calpain-specific cleavage talin degradation product (P < 0.003), and reduced diaphragm force (P < 0.001). Calpain inhibitor III administration prevented endotoxin-induced increases in calpain activity, reduced talin degradation, and attenuated reductions in diaphragm force. Diaphragm-specific force at 150 Hz stimulation was significantly higher in control, endotoxin plus calpain inhibitor III, and calpain inhibitor III alone groups (23 ± 1, 20 ± 1 and 23 ± 1 N/cm2, respectively) than in the endotoxin alone group (15 ± 1 N/cm2) (P < 0.01). This model of sepsis results in significant diaphragm calpain activation and calpain-dependent diaphragm cytoskeletal protein cleavage. Moreover, calpain inhibition attenuates endotoxin-induced diaphragm weakness, suggesting that such inhibitors may be a potential treatment to improve respiratory muscle function in infected patients.

Key Words: diaphragm • endotoxin • calpain • proteolysis


CLINICAL RELEVANCE

Most critically ill patients have significant respiratory muscle weakness. This report identifies a potential therapeutic target that could be exploited to prevent weakness and improve respiratory function in this patient population.

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2010 American Thoracic Society.
  CCM abstracts